Immunotherapy combined with palliative radiation therapy for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer, according to research presented by Hiniker et al (Abstract 215) on October 20, 2015 at the American Society for Radiation Oncology’s...
Cancer is the result of normal cellular functions going wildly awry on a genetic level. That fact has been known for some time, but increasing evidence is showing that the human microbiome, the diverse population of microorganisms within every person, may play a key role in either setting the stage ...
Accelerated partial-breast irradiation was designed to be a faster, more convenient, and potentially safer way for many women with breast cancer to reduce their mortality risk and help keep their cancer from returning after surgery. But a new study shows that despite the availability of accelerated ...
Results of the phase III AHT trial reported in the Journal of Clinical Oncology by Eeles et al suggest that adjuvant hormonal therapy may improve survival in women with epithelial ovarian cancer. The trial, started in 1990, was stopped early due to low recruitment. Study Details In the open-label ...
A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of...
In an analysis reported in the Journal of the National Cancer Institute, Ligibel et al found that body mass index (BMI) at diagnosis was independently prognostic for recurrence-free and overall survival in women with early-stage node-positive breast cancer who received doxorubicin,...
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself, mainly because of the toxic effects of chemotherapy. But a team of surgeons is in the nascent stages of developing a more targeted, less toxic method of treating neuroblastoma patients with chemotherapy....
For younger women with early-stage, noninherited breast cancer on one side, a unilateral mastectomy leads to a slightly higher quality of life and lower costs over the next 20 years compared with contralateral prophylactic mastectomy, according to new study results presented at the 2015 Annual...
In a systematic review and network meta-analysis reported in JAMA Oncology, Fujii et al found that sequential anthracycline-cyclophosphamide and taxane (AC-T) appears to be the most effective adjuvant regimen in early-stage breast cancer in terms of association with overall survival and toxicity....
When integrated into routine oncology care, palliative care can improve symptom burden, quality of life, and patient and caregiver satisfaction. However, because the number of palliative care specialists in the United States is too small to meet the number of patients requiring palliative care, the ...
Disparities in outcomes for children with retinoblastoma suggest unequal access to primary care, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center reported in a study published by Truong et al in JAMA Pediatrics. Although virtually all the children in the study...
As reported in the Journal of Clinical Oncology, ASCO has endorsed the current American College of Chest Physicians (CHEST) guideline on treatment of small cell lung cancer, released in 2013. After review of evidence from an updated literature search covering 2011 to March 2015, an ASCO...
Pembrolizumab (Keytruda), an anti–PD-1 therapy, may be effective as monotherapy in patients with advanced unresectable nasopharyngeal carcinoma whose tumors express programmed cell death-ligand 1 (PD-L1). Data from a phase Ib study, KEYNOTE-028, showed an overall response rate of 22.2% in 27...
At the 2015 European Cancer Congress in Vienna, Austria, early results were announced (Abstract 21LBA) from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (anti–PD-L1; MPDL3280A) in people with locally advanced or metastatic urothelial...
An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...
The effectiveness of antiretroviral therapy in the treatment of patients with human immunodeficiency virus (HIV) has prolonged lives and resulted in cancer becoming increasingly common in this population, with a higher burden than the general population due to impaired immune function, including...
Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently diagnosed only when it has metastasized. Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only 6%. Researchers presented novel findings (Abstract...
Living in overcrowded conditions appears to protect children and young adults against developing a particular type of Hodgkin lymphoma. This protective effect seems to suggest that infections earlier in life may stimulate the immune system to deal with future infections and cancerous cells more...
Colorectal cancer is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumors in younger patients with colorectal cancer may be molecularly distinct from those of...
Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major...
The targeted drug nivolumab (Opdivo) significantly prolonged survival in patients with advanced kidney cancer whose disease had progressed after their first treatment, according to the results (Abstract 3LBA) presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria, and published...
Patients with advanced kidney cancer lived for nearly twice as long without their disease progressing if they were treated with cabozantinib (Cometriq), a drug that inhibits the action of tyrosine kinases. Toni Choueiri, MD, presented the research (Abstract 4LBA) at the Presidential Session of the...
Overall survival data from a phase II study, reported in the Journal of Clinical Oncology by Ellis et al, suggest a benefit of first-line fulvestrant (Faslodex) vs anastrozole in postmenopausal women with estrogen receptor–positive advanced breast cancer. The study protocol was amended to...
Adjuvant radiation therapy may be omitted for elderly women with estrogen receptor–positive, early-stage breast cancer who receive hormone therapy. Limited data exist to guide treatment decision-making for elderly women with triple-negative breast cancer. As some findings thus far have shown...
As reported in the Journal of Clinical Oncology by Ligibel et al, ASCO has issued a statement providing recommendations for obesity clinical trials in cancer survivors. ASCO convened the Research Summit on Advancing Obesity Clinical Trials in Cancer Survivors in November 2014. The meeting involved...
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...
Obesity increases the risk for overall and breast cancer mortality and comorbidity. As reported in the Journal of Clinical Oncology by Rock et al, the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) study has shown that a group-based behavioral intervention can produce...
A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...
Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical...
For children with rare, aggressive, and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study found. Using information from a patient's entire genome helped to suggest personalized treatment options for nearly half of children with cancer and...
Assessing blood plasma levels of certain microRNAs (miRNAs) distinguished individuals with noninvasive pancreatic precancers from healthy individuals and discriminated between patients with high-risk and low-risk neoplasms, according to a preliminary, proof-of-principle study published by...
As reported in the Journal of Clinical Oncology by Masters et al, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC). Recommendations are based on an update committee systematic review of randomized controlled trials...
A genetic test that helps predict whether some women’s breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine. The study found that low-risk patients who had the test appeared to opt for more treatment, and high-risk patients who were...
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical...
Epidermal growth factor receptor (EGFR) mutations are one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with tyrosine kinase inhibitors and median progression-free survival of 10 months, commonly due to emergence of T790M. The genomic...
Adding the monoclonal antibody bevacizumab (Avastin) to chemotherapy for patients with surgically removed non–small cell lung cancer (NSCLC) did not improve overall survival, according to research (Abstract PLEN04.03) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver,...
Scientists have developed a blood test for breast cancer that may be able to identify which patients will suffer a relapse after treatment, months before tumors are visible on hospital scans. The test may uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer...
Concerns about fertility kept one-third of young women with breast cancer surveyed in a recent study from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer recurrence. In addition, the study found fertility concerns led one-quarter of women who started...
In a study reported in the Journal of Clinical Oncology, Vargo et al found that use of consolidative radiotherapy, which continues to decline, is associated with a survival benefit compared with multiagent chemotherapy alone in patients with early-stage diffuse large B-cell lymphoma. Study Details ...
In preclinical and clinical studies reported in the Journal of the National Cancer Institute, Jeong et al found a lack of sprouting angiogenesis in the formation of lymph node metastases, suggesting a potential mechanism for resistance to antiangiogenic treatments in adjuvant settings. The study...
The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...
An endovaginal magnetic resonance imaging technique is more accurate at detecting early-stage cervical cancer than the best available external detection technique, a new study reported. Researchers at The Institute of Cancer Research and The Royal Marsden Hospital found that using an...
Although mammographic screening leads to reductions in breast cancer mortality, some women experience psychosocial side effects and do not benefit from screening, according to a study by Bolejko et al investigating the prevalence and predictors of the psychosocial consequences of false-positive...
A multi-institutional study has found a new set of genes that may indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence. In conjunction with the...
In women with breast cancer, taxane-based chemotherapy—docetaxel and paclitaxel—did not appear to increase the incidence of lymphedema, according to a study by Swaroop et al in Breast Cancer Research and Treatment. However, the investigators did note that adjuvant chemotherapy with...
Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant and three times more likely to die of the skin cancer, suggested new research by a multi-institutional team. The findings, reported by Robbins et al in the Journal of Investigative...
Researchers have shown that magnetic resonance imaging (MRI) can detect the earliest signs of breast cancer recurrence and fast-growing tumors through detecting micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body....
Risk for melanoma has been found to be increased in non-Hodgkin lymphoma (NHL) survivors. In a study reported in the Journal of Clinical Oncology, Lam et al found that T-cell–activating autoimmune diseases and fludarabine use were associated with an increased melanoma risk among patients with ...
In an analysis reported in the Journal of Clinical Oncology, Veluswamy et al found that limited resection was not equivalent to lobectomy in overall survival among older patients with stage IA invasive adenocarcinoma or squamous cell carcinoma of the lung. Among patients with adenocarcinoma,...
Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...